About This Course

This course covers the latest advancement in the pathogenesis, diagnosis and treatment of the malignancies in hematology. The content of  the course can reflect the frontier and latest scientific achievements in the field of hematology, including the  cytogenetics, molecular biological et.al in hematopoietic and blood diseases, such as leukemia, multiple myeloma, myelodysplastic syndrome, primary immune thrombocytopenia, etc. This course is open to all graduate students and foreign students, for it is in full English。

 

Course Staff

  

Chunyan Ji

• Renowned Educator of Shandong University, Second-Grade Professor and Supervisor of Doctoral Students
• Vice-President, Qilu Medical College 
• Vice-President, Qilu Hospital of Shandong University,    Outstanding Academic Leader
• Specially Appointed Expert in Taishan Scholar Scheme
• State Council Expert for Special Allowance
• Outstanding Academic Leader of Medical Science in Shandong Province
• Fellow, Haematology Society of Chinese Medical Association
• Chief Fellow, Haematology Society of Shandong Medical Association
• Standing Committee Member, Society for haematological Malignancies of Chinese Anti-cancer Association
• Alternate Director, Society for Haematological Malignancies of Shandong Anti-Cancer Association
• Editorial Member, Chinese Journal of Haematology

 

  

Daoxin Ma

• Daoxin Ma，Senior technologist，Professor，Doctoral supervisor
• Ph.D，Postdoc of Karolinska Institute of Sweden
• Member of experimental diagnostics group, hematology branch, Chinese Medical Association
• Member of blood pathology working group,  blood tumor Committee, Chinese Anti-cancer Association
• Member of MDS/MPN working group,  blood tumor Committee, Chinese Anti-cancer Association
• Expert reviewer of NSFC and many provincial foundations
• Hosted 6 NSFCs, 5 provincial foundations；Published 40 SCI papers as corresponding author;   Wan 3 provincial awards

 

Shaolei  Zang: MD  PhD

associate chief physician  in Hematology, Shandong University Qilu Hospital;

 

Xiaohong Liang Ph.D, Professor, Department of Immunology, Shandong University

Faculty Appointments:

2017.9 -          Professor, Department of Immunology, Shandong University

2008.10 - 2017.8   Associate Professor, Department of Immunology, Shandong University

2012.12-2013.12   Visiting Scholars, University of Pennsylvania

2006.07 -2008.09  Assistant Professor, Department of Immunology, Shandong University

Major Teaching Responsibilities：

Immunology and Immunology Experiment for 5-year undergraduates, foreign students and graduate students.

Research fields：

1. Pathogenesis and immune therapy of tumor
2. Pathogenesis of metabolism-related liver diseases

 

Jun Peng, Male, born in August, 1968 in China

Deputy Director of the Hematology department and the Cancer Center in Qilu hospital,

Changjiang scholar, doctoral supervisor

Education and Experiences

1986-1991 Bachelor’s Degree, major in clinical medicine in Shandong Medical University

1991-1994 Master degree, candidate of hematology in Shandong Medical University

2000-2003 Doctoral candidate of hematology ITP in Shandong University

1994-1996 Resident Doctor in Shandong Medical University Hospital

1996-2004 Physician in Qilu Hospital of Shandong University

2004-2009 Associate chief physician in Qilu Hospital of Shandong University

2009-present Chief physician, professor, doctoral supervisor in Qilu Hospital of Shandong University

Adjunct Research Positions

Thrombosis and hemostasis committee member of Chinese Society of Hematology, Committee member of Experimental Blood Society of China,

Distinguished Professor of Chang Jiang Scholars Program

Youth Committee of Chinese Society of Hematology,

Member of European Hematology Association (EHA),

Meeting evaluation expert of medical sciences division(National Natural Science Foundation),

Editorial Board Member of Journal of Clinical Hematology,

Editorial Board Member of Chinese Journal of Thrombosis and Hemostasis,

Reviewer of Int Immunopharmacol, Scand J Immunol, Hum Immunology,

New Century Excellent Talents of Education Ministry,

Changjiang scholar.

Research direction

Platelet immunology

Academic Achievements

In recent 5 years, Dr. Jun Peng has published 5 original research papers as the corresponding author/common corresponding author at the most influential magazine Blood（IF 11.841）in the field of blood; he also obtained National Science Foundation for Distinguished Young Scholars and Distinguished Professor of Changjiang Scholars Program. His main academic achievements are as follows:

1. ITP immune pathogenesis and immune tolerance research

1.1 T Cell and immune tolerance research

1.2 Antigen-presenting cell (APC)/mesenchymal stem cell and immune tolerance research

1.3 Abnormal survey on megakaryocytopoiesis

1. Achieved ITP tiered therapy by revealing ITP new pathogenesis

2.1 Built ITP pathogenesis’s system drug challenge test (Eur J Haematol 2011;86:339-346, corresponding author).

2.2 For platelet antibody positive patients, we showed that using IVIG at vein has poor effect for anti-platelet antibody Ib/IX positive patients, so we should avoid choosing IVIG from primary treatment (J Thromb Haematol 2014;12:497-504, corresponding author).

2.3 Rituximab plus recombinant human thrombopoietin vs rituximab monotherapy in corticosteroid-resistant immune thrombocytopenia: a multicenter randomized controlled study, Blood, 2015;125(10):1541-7, common corresponding author. It is chosen by 55th annual meeting of the American Society of Hematology (ASH)（New Orleans, 2013).

Accomplishments and Programs (Recent 5 years)

1. Program name: Study of bone marrow hematopoietic tissue regulating bone marrow plasma cells in immune thrombocytopenia

Item number:91442204

Schedule type: Key support program of NSFC ( Natural Science Foundation of China ) major research plan

Period: 01/2015-12/2018

Funded capital: 3 million yuan

2. Program name: Research of immune tolerance in immune thrombocytopenia

Item number:81125002

Schedule type: National Science Foundation for Distinguished Young Scholars

Period: 01/2012-12/2017

Funded capital: 2 million yuan

3. Program name: The role of inflammasomes in the pathogenesis of primary immune thrombocytopenia

Item number:81370623

Schedule type: National Natural Science Foundation Item

Period: 01/2014-12/2017

Funded capital: 700 thousand yuan

Published papers

1. Zhu XJ, Shi Y, Peng J, Guo CS, Shan NN, Qin P, Ji XB, Hou M. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood. 2009 Dec 17;114(26):5362-7.

2. Zhang XL, Peng J, Sun JZ, Liu JJ, Guo CS, Wang ZG, Yu Y, Shi Y, Qin P, Li SG, Zhang LN, Hou M. De novo induction of platelet-specific CD4(+)CD25(+) regulatory T cells from CD4(+)CD25(-) cells in patients with idiopathic thrombocytopenic purpura. Blood. 2009 Mar 12;113(11):2568-77.

3. Yang L, Wang L, Zhao CH, Zhu XJ, Hou Y, Jun P, Hou M. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. lood. 2010 Nov 18;116(20):4307-16.

4. Liu XG, Ma SH, Sun JZ, Ren J, Shi Y, Sun L, Dong XY, Qin P, Guo CS, Hou M, Peng J. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. lood. 2011 Feb 10;117(6):2061-9.

5. Ma J, Ning YN, Xu M, Hou Y, Wang N, Hou XY, Yu YY, Li H, He WD, Shao LL, Zhou H, Min YN, Liu XG, Shi Y, Qin P, Guo CS, Hou M, Peng J. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia.Blood. 2013 Sep 19;122(12):2074-82.

6. Zhou H, Qiu JH, Wang T, Yu YY, Liu XN, Li X, Wang YW, Hou Y, Li LZ, Liu XG, Hou M, Peng J. Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia.Blood. 2014 Nov 20;124(22):3316-9.

7. Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, Xu RR, Guo CS, Wang XM, Cheng YF, Ni H, Hou M. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study.J Thromb Haemost. 2014 Apr;12(4):497-504.

8. Ren J, Hou XY, Ma SH, Zhang FK, Zhen JH, Sun L, Sun YX, Hao YL, Cheng YF, Hou M, Xu CG, Zhang MH, Peng J. Elevated expression of CX3C chemokine receptor 1 mediates recruitment of T cells into bone marrow of patients with acquired aplastic anaemia. ntern Med. 2014 Nov;276(5):512-24.

9. Zhou H, Xu M, Qin P, Zhang HY, Yuan CL, Zhao HG, Cui ZG, Meng YS, Wang L, Zhou F, Wang X, Li DQ, Bi KH, Zhu CS, Guo CS, Chu XX, Wu QC, Liu XG, Dong XY, Li J, Peng J, Hou M. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.Blood. 2015 Mar 5;125(10):1541-7.

10. Liu XG, Liu S, Feng Q, Liu XN, Li GS, Sheng Z, Chen P, Liu Y, Wei Y, Dong XY, Qin P, Gao C, Ma C, *Zhang L, *Hou M, *Peng J. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP. Blood. 2016;128(6):852-61.

11. Hou Y, Feng Q, Xu M, Li GS, Liu XN, Sheng Z, Zhou H, Ma J, Wei Y, Sun YX, Yu YY, Qiu JH, Shao LL, Liu XG, *Hou M, *Peng J. High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia. Blood. 2016;127(12):1587-97.

12. Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, Liu GQ, *Peng J, *Hou M. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296-302.

13. Kong Z, Qin P, Xiao S, Zhou H, Li H, Yang R, Liu X, Luo J, Li Z, Ji G, Cui Z, Bai Y, Wu Y, Shao L, Peng J, Ma J, Hou M1. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017 Aug 31;130(9):1097-1103.

14. Feng Q, Xu M, Yu YY, Hou Y, Mi X, Sun YX, Ma S, Zuo XY, Shao LL, Hou M, Zhang XH, Peng J*. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia. J Thromb Haemost. 2017 Sep;15(9):1845-1858.

 

Jie Li

 

 

Miao Xu, PhD, MD

Residency in Hematology, Shandong University Qilu Hospital;

Professor, Shandong University, Jinan.

Dr Miao Xu received her Medical Doctor degree (M.D., 2011) and Master’s Degree of Medicine (M.M., 2013) from Shandong University. With Ontario Trillium Scholarship, she did her Ph.D. thesis work in the Department of Laboratory Medicine and Pathobiology at the University of Toronto, Canada. Dr Xu moved back to Shandong University to become a physician scientist in 2018.

currently employed as professor by Shandong University, and also working in Department of Hematology in Shandong University Qilu Hospital. She attended Shandong University from 2006 to 2013 and. In 2013, she was recruited to be a doctorate candidate in University of Toronto, Canada.

 

Ming Hou, PhD, MD

Dean of Department of Hematology, Shandong University Qilu Hospital; 

Chief Physician and Full Professor, Shandong University.

Dr Ming Hou works as the dean of Department of Hematology since 2000. He is a Chief Physician and Full Professor employed by Shandong University in Jinan. He received his Medical Doctor degree (M.D., 1985) and Master’s Degree of Medicine (M.M., 1988) from Shandong Medical College (today, Cheeloo College of Medicine, Shandong University). After he finished the residency and attending in Hematology (1988-1993), he went to Sweden and did his Ph.D. in Gothenburg University (1993-1997). Since 1998, Dr Hou has been recruited as physician and professor by Shandong University Qilu Hospital. His clinical and research interests have been largely in Immune Thrombocytopenia (ITP). He has published over 300 manuscripts predominantly in this area in both clinical studies and basic scientific researches. The contributions and achievements cover the humoral immune and cellular immune mechanism, specific diagnosis, differential diagnosis of ITP, as well as the clinical trials of multiple novel reagents in the treatment of ITP. Many of the studies were published in the distinguished journals in Hematological field, such as Blood, JTH, TH, etc. He has participated in the draft of all versions of Chinese ITP practice guideline. Dr Hou was invited as one of the coauthors in the updated Consensus Report of ITP in 2019, which is the sole Chinese scientist included. He has been a reviewer for multiple journals, e.g. Blood, Br J Haematol, Eur J Haematol and Acta Haematol. Dr Hou has been funded by National Natural Science Foundation of China (NSFC), and acted as leading principle investigator (PI) in 973 National Basic Research Projects.